Literature DB >> 18250362

Effect of telmisartan on nitric oxide--asymmetrical dimethylarginine system: role of angiotensin II type 1 receptor gamma and peroxisome proliferator activated receptor gamma signaling during endothelial aging.

Fortunato Scalera1, Jens Martens-Lobenhoffer, Alicja Bukowska, Uwe Lendeckel, Michael Täger, Stefanie M Bode-Böger.   

Abstract

Telmisartan, in addition to blocking angiotensin (Ang) II type 1 receptor (AT(1)R), activates peroxisome proliferator activated receptor gamma (PPARgamma) signaling that interferes with nitric oxide (NO) system. Because aging of endothelial cells (ECs) is hallmarked by a reduction in NO synthesis, we hypothesized that telmisartan increases NO formation by regulated asymmetrical dimethylarginine (ADMA)-dimethylarginine dimethylaminohydrolase (DDAH)-system through blocking AT(1)R and activating PPARgamma signaling. To test this hypothesis, ECs were cultured with telmisartan, eprosartan, Ang II, and GW9662 (PPARgamma antagonist) until the twelfth passage. During the process of aging, PPARgamma protein expression decreased significantly, whereas the expression of AT(1)R increased. Telmisartan reversed these effects and dose-dependently decreased reactive oxygen species and 8-iso-prostaglandin (PG) F(2alpha) formation. This effect was associated with an upregulated activity and protein expression of DDAH, accompanied by a decrease in ADMA concentration, an increase in NO metabolites, and delayed senescence. Blockade of PPARgamma signaling by GW9662 or PPARgamma small-interference RNA prevented the effect of telmisartan on ADMA-DDAH-NO system. Coincubation with Ang II did not affect the effect of telmisartan-delayed senescence, whereas Ang II itself accelerated endothelial aging. Moreover, AT(1)R blocker eprosartan that did not influence PPARgamma protein expression had no effect on ADMA system and senescence. We have demonstrated that telmisartan mainly by activating PPARgamma signaling can alter the catabolism and release of ADMA as an important cardiovascular risk factor. We therefore propose that telmisartan translationally and posttranslationally upregulated DDAH expression via activation of PPARgamma signaling, causing ADMA to diminish and increase NO synthesis sufficient to delay senescence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250362     DOI: 10.1161/HYPERTENSIONAHA.107.104570

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  17 in total

Review 1.  [Asymmetric dimethylarginine (ADMA): A cardiovascular risk factor].

Authors:  Friedrich Mittermayer; Katarzyna Krzyzanowska; Michael Wolzt
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 2.  Protecting against vascular disease in brain.

Authors:  Frank M Faraci
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-02-18       Impact factor: 4.733

3.  Protective effect of HDL on endothelial NO production: the role of DDAH/ADMA pathway.

Authors:  Zhen-Yu Peng; Shui-Ping Zhao; Bai-Mei He; Dao-Quan Peng; Min Hu
Journal:  Mol Cell Biochem       Date:  2011-01-25       Impact factor: 3.396

Review 4.  Asymmetric dimethylarginine, a biomarker of cardiovascular complications in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Yuzo Yano; Taku Tsunoda; Takashi Ikawa; Toshihiro Matsuo; Fumihiro Ochi; Yoshiki Kusunoki; Masaru Tokuda; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Exp Med       Date:  2015-05-20

5.  Redox Biology of Peroxisome Proliferator-Activated Receptor-γ in Pulmonary Hypertension.

Authors:  Victor Tseng; Roy L Sutliff; C Michael Hart
Journal:  Antioxid Redox Signal       Date:  2019-02-25       Impact factor: 8.401

6.  ADMA injures the glomerular filtration barrier: role of nitric oxide and superoxide.

Authors:  Mukut Sharma; Zongmin Zhou; Hiroto Miura; Andreas Papapetropoulos; Ellen T McCarthy; Ram Sharma; Virginia J Savin; Elias A Lianos
Journal:  Am J Physiol Renal Physiol       Date:  2009-03-18

7.  Asymmetric dimethylarginine in angiotensin II-induced hypertension.

Authors:  Jennifer M Sasser; Natasha C Moningka; Mark W Cunningham; Byron Croker; Chris Baylis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-16       Impact factor: 3.619

Review 8.  Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2016-03-18       Impact factor: 5.046

9.  Telmisartan-induced inhibition of vascular cell proliferation beyond angiotensin receptor blockade and peroxisome proliferator-activated receptor-gamma activation.

Authors:  Koichi Yamamoto; Mitsuru Ohishi; Christopher Ho; Theodore W Kurtz; Hiromi Rakugi
Journal:  Hypertension       Date:  2009-10-12       Impact factor: 10.190

Review 10.  PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

Authors:  Luis Villacorta; Francisco J Schopfer; Jifeng Zhang; Bruce A Freeman; Y Eugene Chen
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.